UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2011
|
CORMEDIX INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
||
|
Delaware
|
001-34673
|
20-5894890
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
745 Rt. 202-206, Suite 303, Bridgewater, NJ
|
08807
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (908) 517-9500
|
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 2, 2011, CorMedix Inc. (the “Company”) held its 2011 Annual Meeting of Stockholders (the “Annual Meeting”).
The following matters were submitted to a vote of the Company’s stockholders at the Annual Meeting: (i) the election of six directors to serve until the Company’s 2012 Annual Meeting of Stockholders and until their successors are duly elected and qualify; and (ii) the ratification of the appointment of J.H. Cohn LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011. The number of shares of the Company’s common stock outstanding and eligible to vote as of April 21, 2011, the record date of the Annual Meeting, was 11,408,274.
Each of the matters submitted to a vote of the Company’s stockholders at the Annual Meeting was approved by the requisite vote of the Company’s stockholders. Set forth below is the number of votes cast for or withheld for director nominees, as well as the number of votes cast for or against, and abstentions and broker non-votes, with respect to the ratification proposal.
|
Nominee
|
For
|
Withheld
|
||||||
|
Bamdad Bastani, Ph.D.
|
3,961,446
|
16,413
|
||||||
|
Richard M. Cohen
|
3,961,446
|
16,413
|
||||||
|
Gary A. Gelbfish, M.D.
|
3,961,446
|
16,413
|
||||||
|
Timothy M. Hofer
|
3,956,496
|
21,363
|
||||||
|
John C. Houghton
|
3,961,446
|
16,413
|
||||||
|
Antony E. Pfaffle, M.D.
|
3,956,496
|
21,363
|
||||||
|
Proposal
|
For
|
Against
|
Abstain
|
Broker
Non-Votes
|
||||
|
Ratification of Appointment of J.H. Cohn LLP
|
8,156,100
|
45,889
|
0
|
0
|
||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
June 6, 2011
|
CORMEDIX INC.
|
||
|
By:
|
/s/ Brian Lenz
|
||
|
Name:
|
Brian Lenz
|
||
|
Title:
|
Chief Financial Officer
|
||